DeVita honored for his research on lymphoma
Yale Cancer Center Director Dr. Vincent T. DeVita Jr. has been selected as the first recipient of the Saul Rosenberg Research Award by the Lymphoma Research Foundation of America (LRFA).
Named in honor of Dr. Saul Rosenberg, Professor Emeritus of Medicine and Radiation Oncology at Stanford University, the prize is intended to recognize an individual who stands out as having played a major role in improved treatments for patients with lymphoma.
The overwhelming choice of LRFA's medical board, DeVita is known worldwide for his significant contributions to the treatment of patients with Hodgkin's disease and other lymphomas. He was instrumental in developing the combination chemotherapy programs that led to the cure of Hodgkin's disease and diffuse large cell lymphoma.
In a letter to DeVita announcing the award, the LRFA medical board wrote: "For the past 40 years, you have made seminal contributions to the treatment of patients with Hodgkin's lymphoma. Many of the principles developed from the treatments you helped to devise over that time have been widely applied, not only to non-Hodgkin's lymphomas but also to many other human malignancies. Your work has both saved lives and contributed at a fundamental level to the science of oncology."
The $50,000 prize can be used by a recipient for a research project of his or her choosing on the diagnosis and treatment of lymphomas.
The Yale Cancer Center is one of a select network of comprehensive cancer centers in the country designated by the National Cancer Institute and the only one in Southern New England. Bringing together the resources of Yale-New Haven Hospital and the Yale University School of Medicine, its mission encompasses patient care, research, cancer prevention and control, community outreach and education.
T H I SW E E K ' SS T O R I E S
Janet Yellen joins Yale Corporation as the newest alumni fellow
MEDICAL SCHOOL NEWS
Bulletin Home|Visiting on Campus|
Calendar of Events|Bulletin Board
|